Across TCGA pan-cancer cohorts, AKR1B15 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AKR1B15 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher AKR1B15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKR1B15 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

DLBC, LUSC, and UCEC are the cancer types where AKR1B15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
LUSC	OS	Median	III,IV	0.147	0.664	.028	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.410	.035	4	view →
SKCM	DFS	Median	II,III,IV	0.839	0.559	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AKR1B15 tumor-vs-normal RNA expression · all AKR1B15 data types